Form 4: Eledon Pharmaceuticals Executive Exercises Stock Options After Performance Milestone

Eledon Pharmaceuticals' General Counsel, Bryan Smith, exercised stock options for 474,350 shares after performance conditions were met.

Summary

• Bryan Smith, General Counsel and Corporate Secretary of Eledon Pharmaceuticals, exercised stock options for 474,350 shares of common stock.
• The options were granted on May 1, 2023, and were subject to both performance-based and time-based vesting criteria.
• The performance-based vesting criteria for 474,350 shares were met on November 21, 2024.
• Time-based vesting criteria for 177,881 shares were met on November 1, 2024.
• The remaining 296,469 shares will vest in equal quarterly installments over three years, ending May 1, 2027.

Sentiment

Score: 7

Explanation: The document reflects a positive event (performance goals met) but is a routine filing, so the sentiment is moderately positive.

Positives

• The exercise of stock options indicates that performance goals were met, which is a positive sign for the company.
• The vesting schedule provides a long-term incentive for the executive.

Industry Context

This is a standard practice for executive compensation in publicly traded companies, particularly in the biotech and pharmaceutical sectors, where stock options are often used to align executive interests with company performance.

Comparison to Industry Standards

• Stock option grants with performance and time-based vesting are common in the pharmaceutical industry.
• Companies like Amgen, Gilead, and Regeneron also use similar vesting schedules for their executive compensation packages.
• The vesting schedule of three years is within the typical range for such grants.

Stakeholder Impact

• Shareholders may view this positively as it indicates that performance goals are being met.
• Employees may see this as a positive sign of company progress.

Next Steps

• The remaining 296,469 shares will continue to vest quarterly over the next three years.

Key Dates

Keywords

stock options, vesting, performance-based, time-based, Eledon Pharmaceuticals, executive compensation, insider trading